# Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

> **NCT02014259** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 71 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Healthy

## Interventions

- **DRUG:** semaglutide

## Key facts

- **NCT ID:** NCT02014259
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-11
- **Primary completion:** 2014-10-24
- **Final completion:** 2014-10-24
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2018-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014259, "Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02014259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*